摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-甲基-1-苯基-1H-吡唑-4-磺酰氯 | 342405-38-3

中文名称
5-甲基-1-苯基-1H-吡唑-4-磺酰氯
中文别名
5-甲基-1-苯基-1-吡咯-4-磺酰氯
英文名称
5-methyl-1-phenyl-1H-pyrazole-4-sulfonyl chloride
英文别名
5-methyl-1-phenylpyrazole-4-sulfonyl chloride
5-甲基-1-苯基-1H-吡唑-4-磺酰氯化学式
CAS
342405-38-3
化学式
C10H9ClN2O2S
mdl
MFCD02681919
分子量
256.713
InChiKey
IRJCRNZTDRODFQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    57 °C
  • 沸点:
    388.8±30.0 °C(Predicted)
  • 密度:
    1.41±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.3
  • 重原子数:
    16
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.1
  • 拓扑面积:
    60.3
  • 氢给体数:
    0
  • 氢受体数:
    3

安全信息

  • 危险品标志:
    C
  • 安全说明:
    S26,S36/37/39,S45
  • 危险类别码:
    R34
  • 海关编码:
    2933199090
  • 储存条件:
    | 室温 |

SDS

SDS:f489d06bf8358f6b9b21a5ab765177a3
查看
Name: 5-Methyl-1-phenyl-1H-pyrazole-4-sulfonyl chloride 95+% Material Safety Data Sheet
Synonym:
CAS: 342405-38-3
Section 1 - Chemical Product MSDS Name:5-Methyl-1-phenyl-1H-pyrazole-4-sulfonyl chloride 95+% Material Safety Data Sheet
Synonym:

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS
CAS# Chemical Name content EINECS#
342405-38-3 5-Methyl-1-phenyl-1H-pyrazole-4-sulfon 95+% unlisted
Hazard Symbols: C
Risk Phrases: 34

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Causes burns.Moisture sensitive.Air sensitive.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Not available.

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Do not induce vomiting. Get medical aid immediately.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:
Treat symptomatically and supportively.

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

Section 7 - HANDLING and STORAGE
Handling:
Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Use only in a chemical fume hood.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Corrosives area. Store under an inert atmosphere.

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 342405-38-3: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white
Odor: odorless - slight odor
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C10H9ClN2O2S
Molecular Weight: 256.71

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials, moisture, exposure to air, contact with water.
Incompatibilities with Other Materials:
Strong oxidizing agents, bases.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, nitrogen oxides, carbon monoxide, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Has not been reported

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 342405-38-3 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
5-Methyl-1-phenyl-1H-pyrazole-4-sulfonyl chloride - Not listed by ACGIH, IARC, or NTP.

Section 12 - ECOLOGICAL INFORMATION


Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.*
Hazard Class: 8
UN Number: 3261
Packing Group: III
IMO
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3261
Packing Group: III
RID/ADR
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3261
Packing group: III

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 34 Causes burns.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 342405-38-3: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 342405-38-3 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 342405-38-3 is not listed on the TSCA inventory.
It is for research and development use only.


SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

  • 作为反应物:
    描述:
    5-甲基-1-苯基-1H-吡唑-4-磺酰氯L-缬氨酸吡啶碳酸氢钠 作用下, 以 甲醇 为溶剂, 反应 2.17h, 生成
    参考文献:
    名称:
    新型杂环磺酰胺作为HIV-1蛋白酶抑制剂的合成
    摘要:
    背景:HIV-1蛋白酶因其在HIV病毒复制中的重要作用而成为药物治疗的主要靶标。几种蛋白酶抑制剂(如洛匹那韦和替普那韦)被证明具有针对HIV病毒的有效抑制活性。由于HIV的高突变率,抗药性仍然是该病毒治疗中的主要问题,新蛋白酶抑制剂的设计和合成是新药开发研究中持续关注的领域。 方法:利用基于肽和基于非肽的蛋白酶抑制剂洛匹那韦和替普那韦的关键结构片段,我们探索设计一些新化合物。 结果:根据洛匹那韦和替普那韦的关键结构片段设计并合成了六种新的蛋白酶抑制剂。设计的新化合物包含杂环基团,例如噻吩,异恶唑和咪唑基团,最好的化合物表现出0.6 nm的蛋白酶抑制活性。 结论:我们通过结合有效的蛋白酶抑制剂洛匹那韦和替普那韦的结构片段,利用基于关键片段的方法制备了一些新型的杂环磺酰胺。这些新设计的化合物中的一些显示出良好的HIV-1蛋白酶抑制活性,这表明该方法可用于发现靶向HIV的新药物前导化合物。
    DOI:
    10.2174/1570178614666171010162204
点击查看最新优质反应信息

文献信息

  • Inhibitors of cytosolic phospholipase A2
    申请人:Wyeth
    公开号:US20030144282A1
    公开(公告)日:2003-07-31
    This invention provides substituted indole compounds of the general formula: 1 and pharmaceutically acceptable salt forms thereof, and methods for using the compounds as inhibitors of the activity of various phospholipase enzymes, particularly phospholipase A 2 enzymes, and for the medical treatment, prevention and inhibition of pain and inflammation.
    这项发明提供了一般式如下的取代吲哚化合物: 1 及其药用可接受的盐形式,以及将这些化合物用作各种磷脂酶酶的抑制剂的方法,特别是磷脂酶A 2 酶,并用于医疗治疗、预防和抑制疼痛和炎症。
  • Structure–activity relationship studies of a novel series of anthrax lethal factor inhibitors
    作者:Sherida L. Johnson、Li-Hsing Chen、Elisa Barile、Aras Emdadi、Mojgan Sabet、Hongbin Yuan、Jun Wei、Donald Guiney、Maurizio Pellecchia
    DOI:10.1016/j.bmc.2009.03.040
    日期:2009.5
    We report on the identification of a novel small molecule inhibitor of anthrax lethal factor using a high-throughput screening approach. Guided by molecular docking studies, we carried out structure–activity relationship (SAR) studies and evaluated activity and selectivity of most promising compounds in in vitro enzyme inhibition assays and cellular assays. Selected compounds were further analyzed
    我们报告了使用高通量筛选方法鉴定炭疽致死因子的新型小分子抑制剂。在分子对接研究的指导下,我们进行了构效关系 (SAR) 研究,并在体外酶抑制试验和细胞试验中评估了最有希望的化合物的活性和选择性。对所选化合物的体外 ADME 特性进行了进一步分析,这使我们能够选择两种化合物进行进一步的初步体内功效研究。所提供的数据代表了进一步药理学和药物化学优化的基础,这些优化可能会产生新的抗炭疽疗法。
  • Survivin inhibitors
    申请人:Wendt D. Michael
    公开号:US20070072833A1
    公开(公告)日:2007-03-29
    Compounds that inhibit survivin, compositions containing the compounds and methods of treating diseases in which survivin is unregulated or overexpressed are disclosed.
    抑制survivin的化合物、含有这些化合物的组合物以及治疗survivin失调或过度表达疾病的方法被揭示。
  • [EN] UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES<br/>[FR] DERIVES DE SULFONAMIDE SUBSTITUES PAR UREE
    申请人:BIOTIE THERAPIES CORP
    公开号:WO2010146236A1
    公开(公告)日:2010-12-23
    The present invention relates to sulphonamide derivatives, whith a urea moiety. The invention also relates to the use of the derivatives as inhibitors of collagen receptor integrins, especially α2β1 integrin inhibitors e.g. in connection with diseases and medical conditions that involve the action of cells and platelets expressing collagen receptors, their use as a medicament, e.g. for the treatment of thrombosis, inflammation, cancer and vascular diseases, pharmaceutical compositions containing them and a process for preparing them. The sulphonamide derivatives have the general formula (I) or (I').
    本发明涉及含有脲基的磺胺类衍生物。该发明还涉及将这些衍生物用作胶原受体整合素的抑制剂,特别是α2β1整合素抑制剂,例如在涉及表达胶原受体的细胞和血小板的疾病和医疗状况中使用,其用作药物,例如用于治疗血栓形成、炎症、癌症和血管疾病,含有它们的药物组合物以及制备它们的方法。这些磺胺类衍生物具有一般式(I)或(I')。
  • Methods for the use of inhibitors of cytosolic phospholipase A2 in the treatment of thrombosis
    申请人:Clerin Valerie
    公开号:US20080009485A1
    公开(公告)日:2008-01-10
    This invention provides methods for the use of substituted indole compounds of the general formula: and pharmaceutically acceptable salt forms thereof. The invention provides methods for the use of the compounds in the treating or preventing thrombosis in a mammal, or preventing progression of symptoms of thrombosis.
    这项发明提供了一种使用通式所示的取代吲哚化合物及其药用盐形式的方法。该发明提供了一种在哺乳动物中治疗或预防血栓形成,或预防血栓形成症状进展的化合物使用方法。
查看更多

同类化合物

伊莫拉明 (5aS,6R,9S,9aR)-5a,6,7,8,9,9a-六氢-6,11,11-三甲基-2-(2,3,4,5,6-五氟苯基)-6,9-甲基-4H-[1,2,4]三唑[3,4-c][1,4]苯并恶嗪四氟硼酸酯 (5-氨基-1,3,4-噻二唑-2-基)甲醇 齐墩果-2,12-二烯[2,3-d]异恶唑-28-酸 黄曲霉毒素H1 高效液相卡套柱 非昔硝唑 非布索坦杂质Z19 非布索坦杂质T 非布索坦杂质K 非布索坦杂质E 非布索坦杂质67 非布索坦杂质65 非布索坦杂质64 非布索坦杂质61 非布索坦代谢物67M-4 非布索坦代谢物67M-2 非布索坦代谢物 67M-1 非布索坦-D9 非布索坦 非唑拉明 雷西纳德杂质H 雷西纳德 阿西司特 阿莫奈韦 阿米苯唑 阿米特罗13C2,15N2 阿瑞匹坦杂质 阿格列扎 阿扎司特 阿尔吡登 阿塔鲁伦中间体 阿培利司N-1 阿哌沙班杂质26 阿哌沙班杂质15 阿可替尼 阿作莫兰 阿佐塞米 镁(2+)(Z)-4'-羟基-3'-甲氧基肉桂酸酯 锌1,2-二甲基咪唑二氯化物 铵2-(4-氯苯基)苯并恶唑-5-丙酸盐 铬酸钠[-氯-3-[(5-二氢-3-甲基-5-氧代-1-苯基-1H-吡唑-4-基)偶氮]-2-羟基苯磺酸基][4-[(3,5-二氯-2-羟基苯 铁(2+)乙二酸酯-3-甲氧基苯胺(1:1:2) 钠5-苯基-4,5-二氢吡唑-1-羧酸酯 钠3-[2-(2-壬基-4,5-二氢-1H-咪唑-1-基)乙氧基]丙酸酯 钠3-(2H-苯并三唑-2-基)-5-仲-丁基-4-羟基苯磺酸酯 钠(2R,4aR,6R,7R,7aS)-6-(2-溴-9-氧代-6-苯基-4,9-二氢-3H-咪唑并[1,2-a]嘌呤-3-基)-7-羟基四氢-4H-呋喃并[3,2-D][1,3,2]二氧杂环己膦烷e-2-硫醇2-氧化物 野麦枯 野燕枯 醋甲唑胺